Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Summary

This is an open-label, non-randomized, multi-center, sequential group, safety, tolerance, and Pharmacokinetic study of a single dose of CMX001 administered at 2 mg/kg of ideal body weight rounded to the closest 20 mg in fasted healthy control subjects compared with that in fasted subjects with moderate and severe hepatic impairment.

Timeline

Start

2011-02

Primary completion

2011-09

Completion

2011-09

Drugs

Indications

No indication recorded.